Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCT-810 in OTC Deficiency
NCT06488313Phase 2Recruiting
- Sponsor
- Arcturus Therapeutics
- Start
- Nov 2024
- Primary completion
- Jun 2026
- Modality
- Gene Editing, Nanoparticles, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ARCT-810 in ornithine transcarbamylase deficiency, sponsored by Arcturus Therapeutics. Primary endpoint: Incidence, severity and dose-relationship of adverse events (AEs) at Day 85. Started Nov 2024; status: recruiting.
02
Drugs
ARCT-810
03
Conditions
ornithine transcarbamylase deficiency
Beyond the preview
Go deeper on NCT06488313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06488313.